Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma

doi:10.12998/wjcc.v7.i13.1599

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7693)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-7) series.

Item

Count

PDF

448

WORD

254

HTML

4016

Figures (1-2)

236

Tables (1-7)

218

Sum=5172

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

960

Download

1561

Sum=2521

Jul 6, 2019 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jul 6, 2019; 7(13): 1599-1610
Published online Jul 6, 2019. doi: 10.12998/wjcc.v7.i13.1599

Table 6 Results of mRECIST in the two groups of liver tumor

HCC treatment response	Group A n = 212	Group B n = 136	P value
CR	5	3
PR	37	28
SD	62	41
PD	108	64
Disease control rate	49.05%	52.94%	0.249

The disease control rate (CR+PR+SD) was no difference between the two groups (P = 0.249). mRECIST: Modified Response Evaluation Criteria in Solid Tumors; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Citation: Luo SH, Chu JG, Huang H, Yao KC. Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World J Clin Cases 2019; 7(13): 1599-1610
URL: https://www.wjgnet.com/2307-8960/full/v7/i13/1599.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i13.1599